Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 May, 2019 04:04 IST
Dr. Reddy's Lab and US arm receives nod for TOSYMRA
Source: IRIS | 28 Jan, 2019, 10.44AM
Comments  |  Post Comment

Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).

TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is the latest product to join the Promius Pharma acute migraine treatment portfolio. The company is working toward commercialization of this product.

"We are excited about the approval of TOSYMRA. This approval affirms our ability to develop well-differentiated products to meet the unmet needs of patients with migraine and HCPs treating them," said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy's (Q,N,C,F)* Laboratories. 

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer